Primary biliary cholangitis (PBC) is a chronic cholestatic disorder in which symptoms exert a direct influence on patients’ ...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September ...
Please provide your email address to receive an email when new articles are posted on . Results presented at The Liver Meeting demonstrated volixibat (Mirum Pharmaceuticals) significantly improved ...
Primary biliary cholangitis (PBC) can deliver a significant blow to patients' quality of life, especially if they are not appropriately diagnosed and treated. "PBC is one of those liver diseases where ...
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of two per 100,000 people per year and an estimated prevalence of 15 per ...
PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo ® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results